FT-207坐剤の泌尿器悪性腫瘍への応用に関する基礎的研究

概要

論文の詳細を見る
FT-207 sappository was administered intrarectally to the experimental animals as well as to the clinical cases. Bioassay study of the serum, bladder wall, prostate and regional lymph nodes detected both FT-207 and 5-FU above the minimum concentration required for the total cell kill. Intrarectal administration of this drug was proved to be rational as an adjunct treatment for urogenital malignancies. The clinical usefulness of FT-207 sappository can be greatly expected in future.